Davenport & CO LLC Eiger Bio Pharmaceuticals, Inc. Transaction History

Davenport & CO LLC

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 20, 2023	SELL	$0.55 - $1.26 $12,650 - $28,980	-23,000 Reduced 9.93%	208,701 $146,000
Q1 2023 Apr 27, 2023	SELL	$0.89 - $2.52 $3,560 - $10,080	-4,000 Reduced 1.7%	231,701 $208,000
Q4 2022 Jan 20, 2023	SELL	$1.02 - $7.48 $17,238 - $126,412	-16,900 Reduced 6.69%	235,701 $0
Q3 2022 Oct 11, 2022	BUY	$6.04 - $9.66 $167,308 - $267,582	27,700 Added 12.32%	252,601 $1.9 Million
Q2 2022 Jul 18, 2022	SELL	$4.99 - $8.96 $23,453 - $42,112	-4,700 Reduced 2.05%	224,901 $1.42 Million
Q1 2022 May 02, 2022	SELL	$3.84 - $9.74 $24,960 - $63,310	-6,500 Reduced 2.75%	229,601 $1.91 Million
Q4 2021 Feb 10, 2022	SELL	$5.12 - $8.19 $723,962 - $1.16 Million	-141,399 Reduced 37.46%	236,101 $1.23 Million
Q3 2021 Oct 14, 2021	BUY	$6.68 - $9.1 $679,356 - $925,470	101,700 Added 36.87%	377,500 $2.52 Million
Q2 2021 Jul 28, 2021	SELL	$7.82 - $9.23 $52,394 - $61,841	-6,700 Reduced 2.37%	275,800 $2.35 Million
Q1 2021 Apr 28, 2021	BUY	$8.44 - $12.66 $25,320 - $37,980	3,000 Added 1.07%	282,500 $2.5 Million
Q4 2020 Jan 13, 2021	BUY	$7.98 - $12.29 $386,232 - $594,836	48,400 Added 20.94%	279,500 $3.44 Million
Q3 2020 Oct 15, 2020	SELL	$7.96 - $12.42 $99,102 - $154,629	-12,450 Reduced 5.11%	231,100 $1.88 Million
Q2 2020 Jul 28, 2020	SELL	$5.4 - $13.37 $27,000 - $66,850	-5,000 Reduced 2.01%	243,550 $2.34 Million
Q1 2020 May 05, 2020	SELL	$4.91 - $14.7 $28,232 - $84,525	-5,750 Reduced 2.26%	248,550 $1.69 Million
Q4 2019 Jan 22, 2020	BUY	$9.77 - $15.66 $2.48 Million - $3.98 Million	254,300 New	254,300 $3.79 Million

748K

Ticker EIGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,966,800
Market Cap $76.1M
Description
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to ...

Get notified when there are updates to the investment portfolio of Davenport & CO LLC, based on Form 13F filings with the SEC.

Stay updated on Davenport & CO LLC with notifications on news.